Frederick Vogt discusses IL-2 stocking levels with potential growth in 2025 due to steady numbers from major U.S. distributors. Improved manufacturing processes lead to increased comfort with preconditioning at ATCs. Month-over-month infusion growth is driven by manufacturing capacity and demand.